List of Excipients in API elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| State of Florida DOH Central Pharmacy | STRIBILD | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate | 53808-0887 | ALUMINUM OXIDE | 2033-04-06 |
| State of Florida DOH Central Pharmacy | STRIBILD | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate | 53808-0887 | CELLULOSE, MICROCRYSTALLINE | 2033-04-06 |
| State of Florida DOH Central Pharmacy | STRIBILD | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate | 53808-0887 | COLLOIDAL SILICON DIOXIDE | 2033-04-06 |
| State of Florida DOH Central Pharmacy | STRIBILD | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate | 53808-0887 | CROSCARMELLOSE SODIUM | 2033-04-06 |
| State of Florida DOH Central Pharmacy | STRIBILD | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate | 53808-0887 | FD&C BLUE NO. 2 | 2033-04-06 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate
Excipient focus: ALUMINUM OXIDE
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants containing ALUMINUM OXIDE
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants not containing ALUMINUM OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants containing CELLULOSE, MICROCRYSTALLINE
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: COLLOIDAL SILICON DIOXIDE
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants containing COLLOIDAL SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| State of Florida DOH Central Pharmacy | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate | 53808-0887 |
| >Company | >Ingredient | >NDC |
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants not containing COLLOIDAL SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate | 61958-1201 |
| Avera McKennan Hospital | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate | 69189-1201 |
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants containing CROSCARMELLOSE SODIUM
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 2
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants containing FD&C BLUE NO. 2
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants not containing FD&C BLUE NO. 2
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants containing FERRIC OXIDE YELLOW
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants containing HYDROXYPROPYL CELLULOSE
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants containing LACTOSE MONOHYDRATE
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants containing MAGNESIUM STEARATE
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate | 61958-1201 |
| Avera McKennan Hospital | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate | 69189-1201 |
| >Company | >Ingredient | >NDC |
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| State of Florida DOH Central Pharmacy | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate | 53808-0887 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 3350
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| State of Florida DOH Central Pharmacy | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate | 53808-0887 |
| >Company | >Ingredient | >NDC |
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants not containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate | 61958-1201 |
| Avera McKennan Hospital | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate | 69189-1201 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants containing POLYVINYL ALCOHOL
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate | 61958-1201 |
| Avera McKennan Hospital | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate | 69189-1201 |
| >Company | >Ingredient | >NDC |
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| State of Florida DOH Central Pharmacy | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate | 53808-0887 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants containing SODIUM LAURYL SULFATE
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants containing TALC
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants containing TITANIUM DIOXIDE
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links